Adimab, LLC - 23 Dec 2025 SCHEDULE 13D/A Report for Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD)

Filing manager: Adimab, LLC
Reporting owner: Adimab, LLC
Security: Invivyd, Inc. Common Stock, $0.0001 par value per share
Beneficially owned shares: 20,262,170 shares
Class ownership: 7.3%
Large-stake signal: Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Ownership
7.3%
Beneficial ownership of this reported class.
Shares
20,262,170 shares
Shares beneficially owned as disclosed.
Event date
23 Dec 2025
Date tied to the ownership event or amendment.
Accepted by SEC
29 Dec 2025
EDGAR acceptance date.
How to read this large-stake filing
Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
Compare this filing with the holder history and issuer page before treating the percentage as a current position.
Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Symbol: IVVD
Shares outstanding: 277,563,973 shares
Form type: SCHEDULE 13D/A
Accepted by SEC: 29 Dec 2025, 16:15:02 UTC
Event date: 23 Dec 2025
Previous filing: 19 Nov 2025
SEC filing: View on sec.gov

Key filing fact

Adimab, LLC disclosed 7.3% ownership in Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD) on 23 Dec 2025.

Key facts

Adimab, LLC filed SCHEDULE 13D/A for Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD).
Disclosed ownership: 7.3%.
Date of event: 23 Dec 2025.

This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares owned	Sole voting power	Shared voting power	Signature	Title	CIK
Adimab, LLC	7.3%	20,262,170	20,262,170		/s/ Philip Chase	Philip Chase, Chief Executive Officer	0001545672

CIK / CUSIP context first

Broader feeds